Skip to main content

Table 3 Brain PFS Heterogeneity by Treatment Effects using Log-rank test

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Best brain response

CR

PR

Any Response

SD ≥ 6mo

SD < 6mo

PD

Total

Log-rank test for treatment,P-value

Treatment before entering the study

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

No.

Median brain PFS, wk (95 % CI)

 

No

0

NE

2

59.3 (NE)

0

NE

1

30.4 (NE)

1

12.6 (NE)

2

9.2 (6.4-12.0)

6

21.5 (12.0-59.3)

0.6281

Excision/GKS/ SRS/FSRT

4

32.4 (21.6-34.7)

0

NE

6

27.5 (20.0-53.7)

2

36.4 (28.1-44.7)

0

NE

0

NE

12

31.4 (22.1-34.7)

 

WBRT

2

84.3 (NE)

4

21.1 (15.9-NE)

13

40.9 (25.0-59.0)

5

35.0 (26.1-NE)

3

17.9 (12.6-24.0)

5

10.7 (4.0-32.6)

32

31.1 (23.7-41.0)

 

Subtotal

6

33.6 (30.4-84.3)

6

42.4 (16.6-NE)

19

32.9 (23.7-54.1)

8

33.2 (28.1-48.6)

4

15.2 (12.6-24.0)

7

10.7 (6.4-12.1)

50

30.6 (24.0-34.7)

 

IT MTX

    

1

17.0 (NE)

      

1

17.0 (NE)

 

Total

6

33.6 (30.4-84.3)

6

42.4 (16.6-NE)

20

32.8 (22.1-54.1)

8

33.2 (28.1-48.6)

4

15.2 (12.6-24.0)

7

10.7 (6.4-12.1)

51

30.4 (23.7-34.7)

 
  1. CR, complete response; FSRT, fractionated stereotactic radiotherapy; GKS, gamma knife surgery; IT MTX, intrathecal methotrexate; PR, partial response; PD, progressive disease; SD, stable disease; SRS, stereotactic radio-surgery; WBRT, whole-brain radiotherapy; NE, not estimable.